Literature DB >> 19874179

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.

Zhaohui Su1, Roy M Gulick, Amy Krambrink, Eoin Coakley, Michael D Hughes, Dong Han, Charles Flexner, Timothy J Wilkin, Paul R Skolnik, Wayne L Greaves, Daniel R Kuritzkes, Jacqueline D Reeves.   

Abstract

The enhanced-sensitivity Trofile assay (Monogram Biosciences) was used to retest coreceptor use at both study screening and study entry for 118 treatment-experienced subjects in AIDS Clinical Trials Group A5211 who had CCR5-tropic (R5) virus detected by the original Trofile assay at study screening. Among 90 recipients of vicriviroc, a significantly (P< .001) greater mean reduction in HIV-1 RNA was observed in 72 subjects with R5 virus versus 15 subjects reclassified as having dual/mixed-tropic viruses at screening: -1.11 versus -0.09 log(10) copies/mL at day 14 and -1.91 versus -0.57 log(10) copies/mL at week 24, respectively. Results suggest that the enhanced-sensitivity assay is a better screening tool for determining patient eligibility for CCR5 antagonist therapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19874179      PMCID： PMC2783913          DOI： 10.1086/648090

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  7 in total

1.  Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.

Authors:  Jeannette M Whitcomb; Wei Huang; Signe Fransen; Kay Limoli; Jonathan Toma; Terri Wrin; Colombe Chappey; Linda D B Kiss; Ellen E Paxinos; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  CCR5 inhibitors: promising yet challenging.

Authors:  Bonaventura Clotet
Journal:  J Infect Dis       Date:  2007-06-05       Impact factor: 5.226

3.  Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.

Authors:  Julie M Strizki; Cecile Tremblay; Serena Xu; Lisa Wojcik; Nicole Wagner; Waldemar Gonsiorek; R William Hipkin; Chuan-Chu Chou; Catherine Pugliese-Sivo; Yushi Xiao; Jayaram R Tagat; Kathleen Cox; Tony Priestley; Steve Sorota; Wei Huang; Martin Hirsch; Gregory R Reyes; Bahige M Baroudy
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

Authors:  Roy M Gulick; Zhaohui Su; Charles Flexner; Michael D Hughes; Paul R Skolnik; Timothy J Wilkin; Robert Gross; Amy Krambrink; Eoin Coakley; Wayne L Greaves; Andrew Zolopa; Richard Reichman; Catherine Godfrey; Martin Hirsch; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2007-06-05       Impact factor: 5.226

5.  Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.

Authors:  Ronald Swanstrom; Ronald J Bosch; David Katzenstein; Hailong Cheng; Hongyu Jiang; Nicholas Hellmann; Richard Haubrich; Susan A Fiscus; Courtney V Fletcher; Edward P Acosta; Roy M Gulick
Journal:  J Infect Dis       Date:  2004-07-23       Impact factor: 5.226

6.  The entry of entry inhibitors: a fusion of science and medicine.

Authors:  John P Moore; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

7.  Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.

Authors:  Jeffrey A Anderson; Hongyu Jiang; Xiao Ding; Leslie Petch; Terri Journigan; Susan A Fiscus; Richard Haubrich; David Katzenstein; Ronald Swanstrom; Roy M Gulick
Journal:  AIDS Res Hum Retroviruses       Date:  2008-05       Impact factor: 2.205
  7 in total
  34 in total

1.  Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.

Authors:  Jeffrey M Jacobson; Jacob P Lalezari; Melanie A Thompson; Carl J Fichtenbaum; Michael S Saag; Barry S Zingman; Paul D'Ambrosio; Nancy Stambler; Yakov Rotshteyn; Andre J Marozsan; Paul J Maddon; Stephen A Morris; William C Olson
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

2.  Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.

Authors:  Patricia Recordon-Pinson; Cathia Soulié; Philippe Flandre; Diane Descamps; Mouna Lazrek; Charlotte Charpentier; Brigitte Montes; Mary-Anne Trabaud; Jacqueline Cottalorda; Véronique Schneider; Laurence Morand-Joubert; Catherine Tamalet; Delphine Desbois; Muriel Macé; Virginie Ferré; Astrid Vabret; Annick Ruffault; Coralie Pallier; Stéphanie Raymond; Jacques Izopet; Jacques Reynes; Anne-Geneviève Marcelin; Bernard Masquelier
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

Review 3.  Personalized medicine: understanding probabilities and managing expectations.

Authors:  Zachary Laksman; Allan S Detsky
Journal:  J Gen Intern Med       Date:  2010-09-28       Impact factor: 5.128

4.  Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1.

Authors:  Wei Huang; Arne Frantzell; Jonathan Toma; Signe Fransen; Jeannette M Whitcomb; Eric Stawiski; Christos J Petropoulos
Journal:  Virology       Date:  2010-11-10       Impact factor: 3.616

Review 5.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

6.  Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.

Authors:  Timothy J Wilkin; Mathew Bidwell Goetz; Robert Leduc; Gail Skowron; Zhaohui Su; Ellen S Chan; Jayyant Heera; Doug Chapman; John Spritzler; Jacqueline D Reeves; Roy M Gulick; Eoin Coakley
Journal:  Clin Infect Dis       Date:  2011-04-01       Impact factor: 9.079

7.  Genotypic tests for determining coreceptor usage of HIV-1.

Authors:  Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2010-12-08       Impact factor: 5.226

8.  HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.

Authors:  P Recordon-Pinson; S Raymond; P Bellecave; A G Marcelin; C Soulie; D Descamps; V Calvez; P R Harrigan; H Fleury; J Izopet; B Masquelier
Journal:  Antimicrob Agents Chemother       Date:  2012-12-03       Impact factor: 5.191

9.  HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.

Authors:  Cécile Tremblay; Isabelle Hardy; Richard Lalonde; Benoit Trottier; Irina Tsarevsky; Louis-Philippe Vézina; Michel Roger; Mark Wainberg; Jean-Guy Baril
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

10.  Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.

Authors:  Jan Weber; Ana C Vazquez; Dane Winner; Richard M Gibson; Ariel M Rhea; Justine D Rose; Doug Wylie; Kenneth Henry; Alison Wright; Kevin King; John Archer; Eva Poveda; Vicente Soriano; David L Robertson; Paul D Olivo; Eric J Arts; Miguel E Quiñones-Mateu
Journal:  J Clin Microbiol       Date:  2013-03-13       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.